» Articles » PMID: 37760647

Antibacterial Properties of the Antimicrobial Peptide Gallic Acid-Polyphemusin I (GAPI)

Overview
Specialty Pharmacology
Date 2023 Sep 28
PMID 37760647
Authors
Affiliations
Soon will be listed here.
Abstract

A novel antimicrobial peptide, GAPI, has been developed recently by grafting gallic acid (GA) to polyphemusin I (PI). The objective of this study was to investigate the antibacterial effects of GAPI on common oral pathogens. This laboratory study used minimum inhibitory concentrations and minimum bactericidal concentrations to assess the antimicrobial properties of GAPI against common oral pathogens. Transmission electron microscopy was used to examine the bacterial morphology both before and after GAPI treatment. The results showed that the minimum inhibitory concentration ranged from 20 μM () to 320 μM (), whereas the minimum bactericidal concentration ranged from 80 μM () to 640 μM (, , and ). Transmission electron microscopy showed abnormal curvature of cell membranes, irregular cell shapes, leakage of cytoplasmic content, and disruption of cytoplasmic membranes and cell walls. In conclusion, the GAPI antimicrobial peptide is antibacterial to common oral pathogens, with the potential to be used to manage oral infections.

Citing Articles

Natural Antimicrobial Peptides and Their Synthetic Analogues for Effective Oral Microflora Control and Oral Infection Treatment-The Role of Ceragenins in the Development of New Therapeutic Methods.

Czarnowski M, Wnorowska U, Luckiewicz M, Dargiewicz E, Spalek J, Okla S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770567 PMC: 11678171. DOI: 10.3390/ph17121725.


Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention.

Roberts A, Younge N, Greenberg R Paediatr Drugs. 2024; 26(3):259-275.

PMID: 38564081 DOI: 10.1007/s40272-024-00626-w.


Photodynamic Antibacterial Therapy of Gallic Acid-Derived Carbon-Based Nanoparticles (GACNPs): Synthesis, Characterization, and Hydrogel Formulation.

Dechsri K, Suwanchawalit C, Patrojanasophon P, Opanasopit P, Pengnam S, Charoenying T Pharmaceutics. 2024; 16(2).

PMID: 38399308 PMC: 10891664. DOI: 10.3390/pharmaceutics16020254.


The Anti-Caries Effects of a Novel Peptide on Dentine Caries: An In Vitro Study.

Zhang O, Niu J, Yu O, Yin I, Mei M, Chu C Int J Mol Sci. 2023; 24(18).

PMID: 37762381 PMC: 10531674. DOI: 10.3390/ijms241814076.

References
1.
Niu J, Yin I, Wu W, Li Q, Mei M, Chu C . Efficacy of the dual-action GA-KR12 peptide for remineralising initial enamel caries: an in vitro study. Clin Oral Investig. 2021; 26(3):2441-2451. DOI: 10.1007/s00784-021-04210-1. View

2.
Mahlapuu M, Bjorn C, Ekblom J . Antimicrobial peptides as therapeutic agents: opportunities and challenges. Crit Rev Biotechnol. 2020; 40(7):978-992. DOI: 10.1080/07388551.2020.1796576. View

3.
Horiuchi M, Washio J, Mayanagi H, Takahashi N . Transient acid-impairment of growth ability of oral Streptococcus, Actinomyces, and Lactobacillus: a possible ecological determinant in dental plaque. Oral Microbiol Immunol. 2009; 24(4):319-24. DOI: 10.1111/j.1399-302X.2009.00517.x. View

4.
Kononen E, Muller H . Microbiology of aggressive periodontitis. Periodontol 2000. 2014; 65(1):46-78. DOI: 10.1111/prd.12016. View

5.
Hajishengallis G . Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol. 2013; 35(1):3-11. PMC: 3947349. DOI: 10.1016/j.it.2013.09.001. View